Form 4: Oncology Institute CEO Sells Shares to Cover Tax Obligations

The CEO of Oncology Institute, Daniel Virnich, sold a portion of his shares to cover tax obligations related to vesting restricted stock units.

Summary

• Daniel Virnich, the CEO of Oncology Institute, sold 4,750 shares of common stock at a price of $0.136 per share on November 20, 2024.
• He also sold an additional 4,977 shares of common stock at the same price on the same day.
• These sales were made to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The sales were executed under a sell-to-cover provision in the RSU agreement.
• The actual prices of the shares sold ranged from $0.136 to $0.168, with the reported price being the volume-weighted average.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among executives in publicly traded companies, particularly when dealing with restricted stock units.
• The price range of $0.136 to $0.168 is within the expected range for such transactions, reflecting the market price of the stock at the time of the sale.
• Similar transactions are regularly reported by executives at other companies, such as those in the biotechnology and healthcare sectors, when they vest their stock options or restricted stock units.

Stakeholder Impact

• The stock sale by the CEO may have a minor impact on the stock price, but it is not expected to be significant given the nature of the transaction.

Key Dates

Keywords

Oncology Institute, Daniel Virnich, stock sale, restricted stock units, tax obligations, Form 4, insider trading